SR9009

Item no.	TMO-T3685-10mM
Manufacturer	TargetMol
CASRN	1379686-30-2
Amount	10 mM x 1 mL (in DMSO)
Quantity options	100 mg 10 mM x 1 mL (in DMSO) 10 mg 1 mg 1 mL 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Neuroscience Molecular Targets for Neuroscience Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Citations	1. Solt LA, et al. Nature. 2012 Mar 29;485(7396):62-8.
Smiles	CCOC(=O)N1CCC(CN(Cc2ccc(s2)[N+]([O-])=O)Cc2ccc(Cl)cc2)C1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	REV-ERB Agonist II, Stenabolic
Shipping Condition	Cool pack
Available
Manufacturer - Targets	Autophagy
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	437, 94
Description	SR9009 (Stenabolic), a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle, and adipose tissue was also altered in mice exposed to SR9009, resulting in increased energy expenditure. In Diet-induced obese mice, SR9009 (100 mg/kg, i.p., b.i.d., for 30 days) could decrease fat mass and markedly improve dyslipidemia and hyperglycemia.
Bioactivity	REV-ERBalpha and REV-ERBbeta nuclear receptors are transcriptional repressors that coordinate circadian rhythm and metabolic pathways in a heme-dependent manner. SR9009 is a REV-ERB agonist that increases the constitutive repression of genes regulated by REV-ERBalpha and REV-ERBbeta with IC50 values of 670 and 800 nM, respectively. Through activation of REV-ERB, SR9009 has been shown to decrease circadian locomotor activity during the dark phase and to alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle and adipose tissue was also shown to be altered in mice exposed to SR9009, resulting in increased energy expenditure.1 Diet-induced obese mice treated with 100 mg/kg SR9009 (i.p. two times a day for 30 days) have been reported to display decreased fat mass and markedly improved dyslipidemia and hyperglycemia.
Pathways	Autophagy
Receptor	Rev-ErbBalpha; Rev-ErbBbeta

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T3685-10mM-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mM x 1 mL (in DMSO)

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question